Glutamate Carboxypeptidase 2 Market Size to Reach $7.0 Billion by 2035

Global glutamate carboxypeptidase 2 market is projected to grow from $2.7 billion in 2025 and is projected to reach $7.0 billion by 2035, growing at a CAGR of 10.0% during the forecast period 2026-2035. The global glutamate carboxypeptidase 2 market is evolving with the growing clinical use of precision-based diagnostic and therapeutic approaches. Increased reliance on molecular targeting has improved disease detection and treatment planning in oncology settings. Hospitals and specialized centers are adopting advanced imaging solutions to support early and accurate diagnosis. Regulatory approvals for targeted therapies are expanding treatment options and strengthening clinical confidence. Investments in radiopharmaceutical manufacturing are improving supply consistency across regions. Greater integration of diagnostics with treatment pathways is shaping a more coordinated care model. These developments are contributing to steady and sustained market progression.

Browse the full report description of “Glutamate Carboxypeptidase 2 Market Size, Share and Trends Analysis Report, By Type (INO-5150, E-2072, and Others), and By Application (Prostate Cancer, Neuropathic Pain, Cognitive Impairment, and Glioblastoma Multiforme), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/glutamate-carboxypeptidase-2-market

The market is also influenced by advancements in production infrastructure and distribution capabilities. Companies are focusing on scaling manufacturing capacity to address the rising demand for specialized products. Cross-border partnerships are enhancing access in emerging healthcare systems. Improvements in logistics and handling are supporting timely product availability. Digital tools are being used to optimize scheduling and patient management in clinical environments. Healthcare providers are emphasizing outcome-based approaches to improve treatment efficiency. These combined factors are expected to support continued expansion and operational maturity of the market over the forecast period.

Global Glutamate Carboxypeptidase 2 Market Competitive Landscape Overview

The key players in the glutamate carboxypeptidase 2 market are Novartis AG, Lantheus Holdings, Inc., Telix Pharmaceuticals Ltd., GE HealthCare Technologies Inc., and Siemens Healthineers AG, among others. The market remains moderately concentrated, with competition centered on product availability and clinical adoption. Participants are emphasizing manufacturing scale and supply chain efficiency to meet growing demand. Regulatory advancements are supporting wider commercialization across regions. Increased collaboration across the value chain is improving access and distribution. Competitive positioning is influenced by innovation, consistency in supply, and market reach.

• In March 2025, Telix Pharmaceuticals Limited announced that the U.S. Food and Drug Administration approved its new PSMA-PET imaging agent Gozellix for prostate cancer, expanding its commercial diagnostic portfolio. The product enhances access to advanced imaging and is expected to be available alongside existing solutions, offering greater flexibility in clinical use. This approval strengthens the company’s position in PSMA-targeted diagnostics and supports broader adoption of precision imaging.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Novartis AG, Lantheus Holdings, Inc., Telix Pharmaceuticals Ltd., GE HealthCare Technologies Inc., and Siemens Healthineers AG, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Glutamate Carboxypeptidase 2 Market Report Segment

By Type

• INO-5150
• E-2072
• Others

By Application

• Prostate Cancer
• Neuropathic Pain
• Cognitive Impairment
• Glioblastoma Multiforme

Global Glutamate Carboxypeptidase 2 Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/glutamate-carboxypeptidase-2-market